文献速递膀胱癌与上尿路尿路上皮癌

光动力诊断与卡介苗治疗的非肌层浸润性膀胱癌复发及进展风险的关联:全国性随访研究

Association Between Photodynamic Diagnosis and Risk of Recurrence and Progression in Bacillus Calmette-guérin-treated Nonmuscle Invasive Bladder Cancer Patients: A Nationwide Follow-up Study.
PubMed 文献 · Urology · 2026-02-10

该研究基于丹麦全国登记数据,纳入2009至2022年间首次诊断非肌层浸润性膀胱癌并接受BCG治疗的4318例患者,其中2388例(55%)在初次经尿道膀胱肿瘤电切术中接受了光动力诊断(PDD)。PDD组1年复发年龄调整相对风险为0.85(95%CI 0.76-0.96),5年相对风险为0.94(95%CI 0.87-1.03)。研究结论认为PDD与BCG治疗结局差异无证据关联,虽1年复发风险小幅降低,但长期复发、进展或BCG反应均无获益。

要点

  • PDD组1年复发风险小幅降低(RR 0.85,95%CI 0.76-0.96)。
  • 5年复发风险无显著差异(RR 0.94,95%CI 0.87-1.03)。
  • PDD与BCG反应、进展风险无显著关联。

核心结论

  • PDD使用与BCG治疗的非肌层浸润性膀胱癌患者的BCG治疗结局差异无证据关联。
  • PDD虽与1年复发风险小幅降低相关,但长期复发、进展或BCG反应均无获益。

研究设计与样本

  • 全国性登记队列研究,使用丹麦健康登记数据。
  • 纳入2009至2022年间首次诊断非肌层浸润性膀胱癌并接受BCG治疗的患者,共4318例,其中2388例(55%)接受PDD辅助诊断。

主要发现

  • PDD组1年复发年龄调整相对风险为0.85(95%CI 0.76-0.96),对比非PDD组。
  • PDD组5年复发相对风险为0.94(95%CI 0.87-1.03)。
  • 充分治疗患者中,PDD组与非PDD组的BCG反应无显著差异。

临床怎么用

  • PDD可用于降低短期复发风险,但不应期望其改善BCG治疗的长期结局。
  • BCG治疗决策中,PDD状态不应作为预测BCG反应或长期进展风险的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether photodynamic diagnosis (PDD) influences recurrence and progression risk in patients with nonmuscle invasive bladder cancer treated with Bacillus Calmette-Guérin (BCG). METHODS: We performed a nationwide cohort study using Danish health registries. Patients with a first-time diagnosis of nonmuscle invasive bladder cancer who received BCG between 2009 and 2022 were included. Patients were followed until death, cystectomy, or December 31, 2023. Exposure was PDD at primary transurethral resection of the bladder. We estimated cumulative incidences and relative risks for recurrence and progression, anid calculated crude and adjusted odds ratios for BCG response according to PDD status. RESULTS: A total of 4318 patients were included, of whom 2388 (55%) underwent PDD-assisted diagnosis. At 1 year, the age-adjusted relative risk for recurrence was 0.85 (95% CI, 0.76-0.96) in the PDD group compared with the non-PDD group. At 5 years, the relative risk was 0.94 (95% CI, 0.87-1.03). No significant differences were observed in BCG response among adequately treated patients between the PDD and non-PDD groups. CONCLUSION: This large registry-based cohort study found no evidence that the use of PDD was associated with differences in BCG treatment outcomes. While PDD was associated with a modest reduction in recurrence risk at 1 year, no long-term benefit was observed regarding recurrence, progression, or BCG response.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hjort PB, Hyldgaard JM, Young-Halvorsen K, et al. Association Between Photodynamic Diagnosis and Risk of Recurrence and Progression in Bacillus Calmette-guérin-treated Nonmuscle Invasive Bladder Cancer Patients: A Nationwide Follow-up Study. Urology. 2026. PMID: 41679343. doi:10.1016/j.urology.2026.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。